Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1984 Feb 15;130(4):383–390.

Strategies for the drug treatment of depression.

A J Cooper, R V Magnus
PMCID: PMC1876118  PMID: 6692235

Abstract

Antidepressants are a useful addition to a physician's therapeutic armamentarium, but because they are used to treat disorders of diverse and largely unknown cause, there is a much greater element of chance associated with their use than with the use of many other types of drugs (e.g., antibiotics and analgesics). Nevertheless, empirically derived treatment schemes, applied systematically, increase the odds of a favourable response and are preferred to haphazard prescribing. To date, no one antidepressant has been shown to be more effective than any other, although the newer agents are alleged to be faster acting, more specific and less toxic than the established drugs. However, generally, such claims have not been proven clinically. Unless there are overwhelming contraindications (e.g., intolerable side effects, an idiosyncratic response or coexisting cardiac disease) the established agents, with their proven efficacy, are preferred initially.

Full text

PDF
383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asberg M., Crönholm B., Sjöqvist F., Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J. 1971 Aug 7;3(5770):331–334. doi: 10.1136/bmj.3.5770.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Braithwaite R. A., Goulding R., Theano G., Bailey J., Coppen A. Plasma concentration of amitriptyline and clinical response. Lancet. 1972 Jun 17;1(7764):1297–1300. doi: 10.1016/s0140-6736(72)91031-8. [DOI] [PubMed] [Google Scholar]
  3. Bridges P. K. ". . . and a small dose of an antidepressant might help". Br J Psychiatry. 1983 Jun;142:626–628. doi: 10.1192/bjp.142.6.626. [DOI] [PubMed] [Google Scholar]
  4. COOPER A. J., KEDDIE K. M. HYPOTENSIVE COLLAPSE AND HYPOGLYCAEMIA AFTER MEBANAZINE--A MONOAMINE-OXIDASE INHIBITOR. Lancet. 1964 May 23;1(7343):1133–1134. doi: 10.1016/s0140-6736(64)91810-0. [DOI] [PubMed] [Google Scholar]
  5. COPPEN A., SHAW D. M., FARRELL J. P. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet. 1963 Jan 12;1(7272):79–81. doi: 10.1016/s0140-6736(63)91084-5. [DOI] [PubMed] [Google Scholar]
  6. Carroll B. J. The dexamethasone suppression test for melancholia. Br J Psychiatry. 1982 Mar;140:292–304. doi: 10.1192/bjp.140.3.292. [DOI] [PubMed] [Google Scholar]
  7. Charney D. S., Menkes D. B., Heninger G. R. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry. 1981 Oct;38(10):1160–1180. doi: 10.1001/archpsyc.1981.01780350094011. [DOI] [PubMed] [Google Scholar]
  8. Cooper A. J., Ashcroft G. Modification of insulin and sulfonylurea hypoglycemia by monoamine-oxidase inhibitor drugs. Diabetes. 1967 Apr;16(4):272–274. doi: 10.2337/diab.16.4.272. [DOI] [PubMed] [Google Scholar]
  9. Coppen A., Shaw D. M., Herzberg B., Maggs R. Tryptophan in the treatment of depression. Lancet. 1967 Dec 2;2(7527):1178–1180. doi: 10.1016/s0140-6736(67)91894-6. [DOI] [PubMed] [Google Scholar]
  10. Earp J. D. Psychosurgery. The position of the Canadian Psychiatric Association. Can Psychiatr Assoc J. 1979 Jun;24(4):353–365. [PubMed] [Google Scholar]
  11. Feighner J. P. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry. 1980 Jul;41(7):250–255. [PubMed] [Google Scholar]
  12. GREENBLATT M., GROSSER G. H., WECHSLER H. DIFFERENTIAL RESPONSE OF HOSPITALIZED DEPRESSED PATIENTS TO SOMATIC THERAPY. Am J Psychiatry. 1964 Apr;120:935–943. doi: 10.1176/ajp.120.10.935. [DOI] [PubMed] [Google Scholar]
  13. Glassman A. H., Bigger J. T., Jr Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry. 1981 Jul;38(7):815–820. doi: 10.1001/archpsyc.1981.01780320095011. [DOI] [PubMed] [Google Scholar]
  14. Glassman A. H., Perel J. M. The clinical pharmacology of imipramine. Implications for therapeutics. Arch Gen Psychiatry. 1973 May;28(5):649–653. doi: 10.1001/archpsyc.1973.01750350029006. [DOI] [PubMed] [Google Scholar]
  15. Glassman A. H., Platman S. R. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res. 1969 Dec;7(2):83–88. doi: 10.1016/0022-3956(69)90013-2. [DOI] [PubMed] [Google Scholar]
  16. Glassman A. H., Shostak M., Kantor S. J., Perel J. M. Plasma levels of imipramine and clinical outcome. Psychopharmacol Bull. 1975 Oct;11(4):27–28. [PubMed] [Google Scholar]
  17. Gram L. F., Reisby N., Ibsen I., Nagy A., Dencker S. J., Bech P., Petersen G. O., Christiansen J. Plasma levels and antidepressive effect of imipramine. Clin Pharmacol Ther. 1976 Mar;19(3):318–324. doi: 10.1002/cpt1976193318. [DOI] [PubMed] [Google Scholar]
  18. Kay D. W., Garside R. F., Fahy T. J. A double-blind trial of phenelzine and amitriptyline in depressed out-patients. A possible differential effect of the drugs on symptoms. Br J Psychiatry. 1973 Jul;123(572):63–67. doi: 10.1192/bjp.123.1.63. [DOI] [PubMed] [Google Scholar]
  19. Keller M. B., Klerman G. L., Lavori P. W., Fawcett J. A., Coryell W., Endicott J. Treatment received by depressed patients. JAMA. 1982 Oct 15;248(15):1848–1855. [PubMed] [Google Scholar]
  20. Kendell R. E. The present status of electroconvulsive therapy. Br J Psychiatry. 1981 Oct;139:265–283. doi: 10.1192/bjp.139.4.265. [DOI] [PubMed] [Google Scholar]
  21. Klerman G. L. Psychotherapies and somatic therapies in affective disorders. Psychiatr Clin North Am. 1983 Mar;6(1):85–103. [PubMed] [Google Scholar]
  22. Kragh-Sorensen P., Hansen C. E., Larsen N. E., Nasestoft J., Hvidberg E. F. Long-term treatment of endogenous depression with nortriptyline with control of plasma levels. Psychol Med. 1974 May;4(2):174–180. doi: 10.1017/s0033291700042008. [DOI] [PubMed] [Google Scholar]
  23. Kragh-Sørensen P., Asberg M., Eggert-Hansen C. Plasma-nortriptyline levels in endogenous depression. Lancet. 1973 Jan 20;1(7795):113–115. doi: 10.1016/s0140-6736(73)90192-x. [DOI] [PubMed] [Google Scholar]
  24. Kupfer D. J., Foster F. G., Reich L., Thompson S. K., Weiss B. EEG sleep changes as predictors in depression. Am J Psychiatry. 1976 Jun;133(6):622–626. doi: 10.1176/ajp.133.6.622. [DOI] [PubMed] [Google Scholar]
  25. Mendels J., Amin M. M., Chouinard G., Cooper A. J., Miles J. E., Remick R. A., Saxena B., Secunda S. K., Singh A. N. A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry. 1983 May;44(5 Pt 2):118–120. [PubMed] [Google Scholar]
  26. Montgomery S. A. Measurement of serum drug levels in the assessment of antidepressants. Br J Clin Pharmacol. 1980 Nov;10(5):411–416. doi: 10.1111/j.1365-2125.1980.tb01781.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. PARE C. M. POTENTIATION OF MONOAMINE-OXIDASE INHIBITORS BY TRYPTOPHAN. Lancet. 1963 Sep 7;2(7306):527–528. doi: 10.1016/s0140-6736(63)90271-x. [DOI] [PubMed] [Google Scholar]
  28. Pankratz W. J. Electrtoconvulsive therapy: the position of the Canadian Psychiatric Association. Can J Psychiatry. 1980 Oct;25(6):509–514. doi: 10.1177/070674378002500609. [DOI] [PubMed] [Google Scholar]
  29. Paul S. M., Rehavi M., Skolnick P., Ballenger J. C., Goodwin F. K. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry. 1981 Dec;38(12):1315–1317. doi: 10.1001/archpsyc.1981.01780370017001. [DOI] [PubMed] [Google Scholar]
  30. Paykel E. S., Parker R. R., Penrose R. J., Rassaby E. R. Depressive classification and prediction of response to phenelzine. Br J Psychiatry. 1979 Jun;134:572–581. doi: 10.1192/bjp.134.6.572. [DOI] [PubMed] [Google Scholar]
  31. Paykel E. S., Rowan P. R., Parker R. R., Bhat A. V. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry. 1982 Sep;39(9):1041–1049. doi: 10.1001/archpsyc.1982.04290090035008. [DOI] [PubMed] [Google Scholar]
  32. Pecknold J. C., Ban T. A., Lehmann H. E., Klingner A. A clinical trial with nomifensin, a new antidepressant drug. Int J Clin Pharmacol Biopharm. 1975 Jun;11(4):304–308. [PubMed] [Google Scholar]
  33. REES L., DAVIES B. A controlled trial of phenelzine ("Nardil") in the treatment of severe depressive illness. J Ment Sci. 1961 May;107:560–566. doi: 10.1192/bjp.107.448.560. [DOI] [PubMed] [Google Scholar]
  34. Raskin A., Schulterbrandt J. G., Reatig N., Crook T. H., Odle D. Depression subtypes and response to phenelzine, diazepam, and a placebo. Results of a nine hospital collaborative study. Arch Gen Psychiatry. 1974 Jan;30(1):66–75. doi: 10.1001/archpsyc.1974.01760070050008. [DOI] [PubMed] [Google Scholar]
  35. Raskin A., Schulterbrandt J. G., Reatig N., McKeon J. J. Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry. 1970 Aug;23(2):164–173. doi: 10.1001/archpsyc.1970.01750020068009. [DOI] [PubMed] [Google Scholar]
  36. Schildkraut J. J. Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: preliminary findings. Am J Psychiatry. 1973 Jun;130(6):695–699. doi: 10.1176/ajp.130.6.695. [DOI] [PubMed] [Google Scholar]
  37. Schildkraut J. J., Orsulak P. J., Schatzberg A. F., Gudeman J. E., Cole J. O., Rohde W. A., LaBrie R. A. Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Arch Gen Psychiatry. 1978 Dec;35(12):1427–1433. doi: 10.1001/archpsyc.1978.01770360031003. [DOI] [PubMed] [Google Scholar]
  38. Shaw D. M. The practical management of affective disorders. Br J Psychiatry. 1977 May;130:432–451. doi: 10.1192/bjp.130.5.432. [DOI] [PubMed] [Google Scholar]
  39. Sheehan D. V., Ballenger J., Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan;37(1):51–59. doi: 10.1001/archpsyc.1980.01780140053006. [DOI] [PubMed] [Google Scholar]
  40. Solyom L., Heseltine G. F., McClure D. J., Solyom C., Ledwidge B., Steinberg G. Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Can Psychiatr Assoc J. 1973 Feb;18(1):25–32. doi: 10.1177/070674377301800106. [DOI] [PubMed] [Google Scholar]
  41. Tam W., Young J. P., John G., Lader M. H. A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients. Br J Psychiatry. 1982 Mar;140:287–291. doi: 10.1192/bjp.140.3.287. [DOI] [PubMed] [Google Scholar]
  42. Tyrer P., Candy J., Kelly D. Phenelzine in phobic anxiety: a controlled trial. Psychol Med. 1973 Feb;3(1):120–124. doi: 10.1017/s0033291700046419. [DOI] [PubMed] [Google Scholar]
  43. Vohra J., Burrows G. D., Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med. 1975 Feb;5(1):7–11. doi: 10.1111/j.1445-5994.1975.tb03247.x. [DOI] [PubMed] [Google Scholar]
  44. Ziegler V. E., Clayton P. J., Taylor J. R., Tee B., Biggs J. T. Nortriptyline plasma levels and therapeutic response. Clin Pharmacol Ther. 1976 Oct;20(4):458–463. doi: 10.1002/cpt1976204458. [DOI] [PubMed] [Google Scholar]
  45. van Bladeren P. J., Breimer D. D., Rotteveel-Smijs G. M., Hoogeterp J. J., Mohn G. R., de Groot A., van Zeeland A. A., van der Gen A. The activating role of glutathione in the mutagenicity of 1,2-dibromoethane. Adv Exp Med Biol. 1981;136(Pt A):809–820. doi: 10.1007/978-1-4757-0674-1_63. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES